News coverage about Molecular Templates (NASDAQ:MTEM) has trended somewhat positive on Thursday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Molecular Templates earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.8908470911874 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of MTEM stock traded down $0.22 during trading hours on Thursday, hitting $5.00. 4,172 shares of the company’s stock were exchanged, compared to its average volume of 62,700. The company has a market capitalization of $155.90 million, a PE ratio of -2.32 and a beta of 3.00. Molecular Templates has a 12-month low of $4.61 and a 12-month high of $13.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.33 and a current ratio of 3.33.
Molecular Templates (NASDAQ:MTEM) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported $0.36 EPS for the quarter, topping the consensus estimate of ($0.25) by $0.61. The firm had revenue of $1.37 million for the quarter. Molecular Templates had a negative net margin of 509.53% and a negative return on equity of 22.67%. research analysts predict that Molecular Templates will post -1.57 EPS for the current year.
Several research analysts have commented on the stock. ValuEngine downgraded shares of Molecular Templates from a “hold” rating to a “sell” rating in a research note on Friday, July 6th. Zacks Investment Research raised shares of Molecular Templates from a “sell” rating to a “hold” rating in a research note on Thursday, June 7th.
Molecular Templates Company Profile
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.
Featured Article: Diversification in Your Portfolio
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.